NCT01204840 is a Phase 2 clinical trial of Growth Hormone in Infertility, sponsored by Ottawa Fertility Centre.

Who is sponsoring NCT01204840?

NCT01204840 is sponsored by Ottawa Fertility Centre.

What drugs are being tested in NCT01204840?

Interventions in NCT01204840: Growth Hormone, Patch protocol.

What condition does NCT01204840 study?

NCT01204840 studies Infertility, Poor Ovarian Reserve.

Is NCT01204840 still recruiting?

NCT01204840 is currently completed. Last updated 29 June 2015.

Last reviewed 2015-06-29 · How we verify

NCT01204840

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Co-treatment With Recombinant Growth Hormone (GH) in Poor Responders Treated by in Vitro Fertilization (IVF-ET)

Completed Phase 2 Last updated 29 June 2015

What this trial tests

Phase 2 trial testing Growth Hormone in Infertility in 38 participants. Completed in 1 May 2015.

Timeline

1 September 2010

Primary endpoint
1 May 2015

1 May 2015

Quick facts

Lead sponsor	Ottawa Fertility Centre
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	1 September 2010
Primary completion	1 May 2015
Estimated completion	1 May 2015
Sites	1 location across Canada

Drugs / interventions tested

Growth Hormone — full drug profile →
Patch protocol — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →
Poor Ovarian Reserve — all drugs for Poor Ovarian Reserve →

Sponsor

Ottawa Fertility Centre — full company profile →

Who can join

Adults 18 to 41, female only, with Infertility or Poor Ovarian Reserve. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

number of mature oocytes retrieved
Time frame: 8-12 weeks from IVF start date

Sponsor's own description

The purpose of this study is to determine if growth hormone given 4 weeks before as well as during a cycle of in vitro fertilization will improve outcomes in women who have had previous failure with IVF treatment cycles using high doses of follicle stimulating medications and had a poor response (less than 6 follicles).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Growth Hormone

Trials testing the same drug.

NCT05447208 — Effect of GH on the Blastocyst Euploid Rate in AMA Patients · Phase 3 · recruiting
NCT05253287 — Growth Hormone in Decompensated Liver Cirrhosis · Phase 2, PHASE3 · completed
NCT05187377 — A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism · Phase 2 · completed
NCT05089344 — Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlle · NA · unknown
NCT04532554 — Growth Hormone in Obese Cases With Covid-19 · Phase 4 · withdrawn

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01204840 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Fertility Centre
Last refreshed: 29 June 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01204840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing